SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
SEC Accession No. 0001213900-24-050843
Filing Date
2024-06-07
Accepted
2024-06-07 17:04:56
Documents
6
Effectiveness Date
2024-06-07

Document Format Files

Seq Description Document Type Size
1 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 ea0207285-s8pos_jasper.htm S-8 POS 82613
2 OPINION OF PAUL HASTINGS LLP ea020728502ex5-1_jasper.htm EX-5.1 22125
3 CONSENT OF PRICEWATERHOUSECOOPERS LLP ea020728502ex23-1_jasper.htm EX-23.1 1597
4 GRAPHIC ex5-1_001.jpg GRAPHIC 8762
5 GRAPHIC ex5-1_002.jpg GRAPHIC 9746
6 GRAPHIC ex5-1_003.jpg GRAPHIC 6204
  Complete submission text file 0001213900-24-050843.txt   141972
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 POS | Act: 33 | File No.: 333-270361 | Film No.: 241030533
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)